{"id":8769,"date":"2026-10-07T08:35:15","date_gmt":"2026-10-07T12:35:15","guid":{"rendered":"https:\/\/cqdm.org\/?page_id=8769"},"modified":"2026-10-07T10:04:15","modified_gmt":"2026-10-07T14:04:15","slug":"accelerating-the-development-of-biopharmaceutical-start-ups","status":"publish","type":"page","link":"https:\/\/cqdm.org\/en\/accelerating-the-development-of-biopharmaceutical-start-ups\/","title":{"rendered":"Accelerating the Development of Biopharmaceutical Start-ups"},"content":{"rendered":"\n

Bringing a new therapy or enabling technology to market requires far more than funding alone. In addition to supporting promising innovations, CQDM provides access to strategic resources, specialized expertise, and potential partners that can play a decisive role, particularly at critical stages of development.<\/p>\n\n\n\n

From emerging startups to growing SMEs, CQDM helps drive life sciences innovation in Quebec. Leveraging strong connections across academia, industry, and government, CQDM guides innovators toward the right resources, experts, and partners at every stage of their journey, from scientific discovery through commercialization.<\/p>\n\n\n\n

\n\n\n\n

Understanding the Challenges Facing Quebec’s Biopharmaceutical Startups<\/h2>\n\n\n\n

The development of a therapeutic product presents challenges that distinguish it from other types of technological innovation. It is a lengthy process that spans many years, requires substantial investment, and carries a high risk of failure. As a result, the value of a startup depends on its ability to progressively reduce scientific, clinical, regulatory, and manufacturing uncertainties while achieving milestones that can attract investment capital.<\/p>\n\n\n\n

Quebec benefits from world-class biomedical research, state-of-the-art infrastructure, and strong expertise in drug discovery and development. However, these strengths alone are not always enough to bridge the gap between a scientific breakthrough and a biopharmaceutical company capable of reaching key development milestones and securing investment. As a result, many promising innovations remain trapped in the so-called “valley of death.”<\/p>\n\n\n\n

To better understand the barriers that undermine this transition, CQDM conducted a study based on 61 consultations with entrepreneurs, support organizations, investors, industry associations, pharmaceutical companies, and specialized consultants. The resulting white paper highlights seven recurring challenges that influence the development of biopharmaceutical startups in Quebec. It also outlines five actionable recommendations, grounded in existing strengths within Quebec’s ecosystem, to better prepare companies for critical milestones and strengthen the conditions required for value creation and capital attraction.<\/p>\n\n\n\n

This initiative was made possible through the financial support of the Government of Quebec. CQDM gratefully acknowledges its commitment to advancing Quebec’s biopharmaceutical sector.<\/p>\n\n\n\n

\n
\n
\n
\n
\n
Download the White Paper<\/a><\/div>\n<\/div>\n\n\n\n
\"\"<\/figure>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n\n\n\n

Navigating the Ecosystem: An Interactive Directory of Biotech Support Organizations<\/h2>\n\n\n\n

The journey of a biotechnology startup is marked by complex strategic decisions. From validating a scientific concept to building a company capable of attracting significant investment, every stage requires targeted support and access to the right resources. To address this need, CQDM has mapped the organizations that support Quebec biotech entrepreneurs in their business development efforts.<\/p>\n\n\n\n

This resource brings together organizations that provide growth-focused support, including training, mentorship, access to experts, networking opportunities, business model validation, and preparation for commercialization and investor presentations.<\/p>\n\n\n\n

\n
Explore the Biotech Support Organizations Directory<\/a><\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n\n\n\n

Accessing Biopharmaceutical Expertise Through The AReNA Support Initiative<\/h2>\n\n\n\n

The right expertise at the right time can significantly influence the trajectory of a project.<\/strong><\/p>\n\n\n\n

Through AReNA, CQDM and its partners are developing initiatives designed to facilitate startups’ access to the biopharmaceutical expertise needed at various stages of development.<\/p>\n\n\n\n

Available at a reduced cost, these resources include training programs, structured support pathways, and targeted consultations with industry experts. Priority is given to RNA-focused startups, companies incubated or accelerated by a Quebec-based organization, and businesses participating in innovation projects funded by the Government of Quebec. These services help teams make more informed decisions, anticipate upcoming milestones, and strengthen their development strategies.<\/p>\n\n\n\n

Companies participating in CQDM-supported R&D projects may be eligible for AReNA support services. For more information, please contact us at ARN@cqdm.org<\/a>.<\/strong><\/p>\n\n\n\n

\n
Learn More About AReNA and the Support Initiative<\/a><\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

Companies participating in CQDM programs may be eligible for some of these opportunities.<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Bringing a new therapy or enabling technology to market requires far more than funding alone. In addition to supporting promising innovations, CQDM provides access to strategic resources, specialized expertise, and potential partners that can play a decisive role, particularly at critical stages of development. From emerging startups to growing SMEs, CQDM helps drive life sciences…<\/p>\n","protected":false},"author":2,"featured_media":8835,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-8769","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/pages\/8769","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/comments?post=8769"}],"version-history":[{"count":8,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/pages\/8769\/revisions"}],"predecessor-version":[{"id":8874,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/pages\/8769\/revisions\/8874"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media\/8835"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=8769"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}